Investment Rating - The report maintains an investment rating of "Outperform the Market - A" [6] Core Insights - The report highlights the promising clinical data of BaiLi Tianheng's EGFR/HER3 dual antibody ADC, iza-bren, for treating EGFR mutation lung cancer, which shows potential for further clinical advancement [2][3][20][21][23] Summary by Sections Weekly New Drug Market Review - From September 8 to September 14, 2025, the top five gainers in the new drug sector were: - Saintno Pharmaceutical (+32.00%) - Junshengtai (+23.73%) - Canaan Bio (+20.43%) - Rongchang Bio (+16.52%) - Hengrui Medicine (+11.91%) - The top five losers were: - Basestone Pharmaceuticals (-18.90%) - Laika Pharmaceuticals (-18.12%) - Gilead Sciences (-16.93%) - Maiwei Bio (-14.41%) - Yifang Bio (-12.46%) [1][15] Recommended Stocks to Watch - The report suggests focusing on several potential catalysts in the sector, including academic conferences, business development realizations, and insurance negotiations. Key stocks to watch include: 1. Potential overseas licensed MNC heavyweights: - Differentiated GLP-1 assets: Zhongsheng Pharmaceutical, Gilead Sciences, Borui Pharmaceutical, Kangyuan Pharmaceutical - Upgraded PD-1 products: Kangfang Bio and other PD-1/VEGF assets, Innovent Biologics - Breakthroughs in autoimmune fields: Yifang Bio, China Antibody - Innovative target ADCs: Fuhong Hanlin, Shiyao Group 2. MNC-certified products with high overseas volume certainty: - Upgraded PD-1 products: Sanofi Pharmaceutical - GLP-1 assets: Lianbang Pharmaceutical - ADC assets: Kelong Botai, BaiLi Tianheng 3. Products likely to benefit from insurance negotiations and innovative drug directories [2][20] New Drug Industry Focus Analysis - At the recent 2025 World Lung Cancer Conference (WCLC), BaiLi Tianheng presented results from two studies on its EGFR×HER3 dual antibody ADC, iza-bren, showing excellent clinical data in both first-line and second-line treatments for advanced or metastatic EGFR mutation NSCLC. The results indicate a promising future for its application in relevant indications [2][20][21] New Drug Approval and Acceptance Status - No new drug or new indication applications were approved this week, but seven new drug or new indication applications were accepted [3][25] Clinical Application Approval and Acceptance Status - This week, 41 new drug clinical applications were approved, and 46 new drug clinical applications were accepted [9][28]

Group 1 - The A-share market closed at a precise 3892.74 points, indicating strong market sentiment and anticipation for upcoming events [1] - Morgan Stanley predicts that the Federal Reserve will initiate a 0.25% rate cut at each remaining meeting this year, which is expected to significantly impact the A-share market [1] - The A-share market's valuation, with a PE ratio of 12.8 times for the CSI 300 index, presents an attractive opportunity compared to US markets, leading to a substantial inflow of foreign capital [1] Group 2 - The three favored sectors in a bull market are technology, cyclical, and financial stocks, with technology benefiting from ample liquidity and high growth potential [2] - The margin trading balance has surpassed 2.15 trillion, indicating strong market confidence and activity [2] Group 3 - The Chinese innovative drug sector is experiencing significant policy support, with the government emphasizing accelerated technology development and commercialization [3] - Collaborations between Chinese companies and international firms, such as the partnership between 3SBio and Pfizer, have resulted in record upfront payments, showcasing the strength of China's innovative drug industry [3] - The Hong Kong stock market's innovative drug sector rose by 2.79% following the announcement of favorable policies, reflecting market confidence [3] Group 4 - The A-share market showed resilience with a weekly increase of 1.52% for the Shanghai Composite Index and a 5.48% rise for the Sci-Tech 50 Index [4] - The upcoming Federal Reserve rate cut is anticipated to drive significant capital inflows, with a target of maintaining a trading volume above 3 trillion for three consecutive days [4] - Key sectors to watch include technology, particularly in computing power and robotics, as well as cyclical stocks like rare earths and gold [4] Group 5 - Investment strategies suggest holding onto key sectors despite short-term volatility, with a focus on technology stocks and cyclical sectors ahead of the anticipated rate cut [6] - The brokerage sector is positioned for potential growth as market activity increases, with current price-to-book ratios indicating a favorable entry point [6] - Historical trends suggest that market corrections in a bull market present valuable buying opportunities, with foreign capital showing consistent net inflows [6]

Market Overview - On September 12, the Hang Seng Index rose by 1.16%, closing at 26,388.16 points, with a net inflow of HKD 7.331 billion through the southbound trading channel [2] - The total trading volume for the southbound trading on that day was HKD 157.992 billion, with a net buying amount of HKD 7.331 billion [2] Southbound Trading Details - The Shanghai Stock Exchange's southbound trading had a total transaction amount of HKD 97.259 billion, with a net selling of HKD 1.487 billion; while the Shenzhen Stock Exchange's southbound trading had a transaction amount of HKD 60.733 billion, with a net buying of HKD 8.818 billion [2] - The most actively traded stock in the Shanghai southbound trading was Alibaba-W, with a transaction amount of HKD 87.744 billion and a net buying of HKD 2.076 billion, closing with a price increase of 5.44% [2] - In the Shenzhen southbound trading, Alibaba-W also led with a transaction amount of HKD 63.889 billion and a net buying of HKD 2.304 billion, maintaining the same closing price increase of 5.44% [3] Active Stocks Summary - The top ten actively traded stocks in the southbound trading included Alibaba-W, Meituan-W, and SMIC, with transaction amounts of HKD 87.744 billion, HKD 50.99 billion, and HKD 37.02 billion respectively [2] - Meituan-W had the highest net selling amount of HKD 1.635 billion, closing flat [2] - Other notable stocks included Tencent Holdings and Xiaomi Group, with transaction amounts of HKD 32.17 billion and HKD 23.17 billion respectively, and Tencent saw a net buying of HKD 0.744 billion [3] Additional Stock Performance - The stock performance of various companies showed that 8 out of the top ten stocks had net buying, with Alibaba-W leading at HKD 2.304 billion [3] - The stock of Sanofi had the highest net selling amount of HKD 0.295 billion, while its closing price increased by 1.81% [4]

Group 1 - The net buying of stocks by southbound funds includes Alibaba-W at 4.38 billion, Tencent Holdings at 0.929 billion, Pop Mart at 0.642 billion, Hua Hong Semiconductor at 0.401 billion, Kangfang Biotech at 0.225 billion, and Yaojie Ankang-B at 0.18 billion, while net selling includes Meituan-W at 1.682 billion, 3SBio at 0.294 billion, UBTECH at 0.228 billion, and Bilibili-W at 0.138 billion [1] - Southbound funds have continuously net bought Alibaba for 16 days, totaling 41.52389 billion HKD, while net selling Meituan for 4 days, totaling 2.70959 billion HKD [3] Group 2 - Alibaba and Baidu have started using self-designed chips to train their AI models, partially replacing chips produced by Nvidia. Alibaba's Tongyi Qianwen has released the next-generation foundational model architecture Qwen3-Next and open-sourced the Qwen3-Next-80B-A3B series model based on this architecture [4] - Pop Mart has launched its first gold series products under its jewelry brand popop, with the most expensive item being a gold ornament weighing approximately 41 grams, priced over 56,000 RMB. The price of the gold series products will not fluctuate with gold prices but will vary based on craftsmanship, with prices per gram mainly concentrated between 1,300 to 1,700 RMB [4] - Yaojie Ankang's stock price has surged over 18 times since its IPO price of 13.15 HKD in less than three months. The company announced that its core product, Tengrutin combined with Fulvestrant, has received clinical implied approval from the National Medical Products Administration of China for a Phase II clinical trial for recurrent or metastatic breast cancer [4] Group 3 - Meituan is considering issuing dim sum bonds, with multiple investment banks gauging fixed-income investors' interest in potential offshore RMB bonds. Discussions are still in the preliminary stages regarding details such as term, scale, and issuance timing [5] - If successfully priced, this will be Meituan's first issuance of dim sum bonds. Meituan has a 750 million USD bond with a 2.125% coupon maturing on October 28. Last September, Meituan raised a total of 2.5 billion USD through the issuance of two USD bonds [6]

Group 1 - On September 12, 2025, Alibaba-W (09988), Meituan-W (03690), and SMIC (00981) were the top three companies by trading volume in the Southbound Stock Connect, with transaction amounts of 87.74 billion, 50.99 billion, and 37.02 billion respectively [1] - In the Southbound Stock Connect for Shenzhen-Hong Kong, Alibaba-W (09988), Tencent Holdings (00700), and Xiaomi Group-W (01810) led the trading volume, with transaction amounts of 63.89 billion, 32.17 billion, and 23.17 billion respectively [1] Group 2 - In the Southbound Stock Connect (Hong Kong), the top active trading companies included: - Alibaba-W (09988) with a net buy of +20.76 billion - Tencent Holdings (00700) with a net buy of +1.85 billion - Meituan-W (03690) with a net sell of -16.35 billion [2] - In the Southbound Stock Connect (Shenzhen), the top active trading companies included: - Alibaba-W (09988) with a net buy of +23.04 billion - Tencent Holdings (00700) with a net buy of +7.44 billion - Meituan-W (03690) with a net sell of -46.59 million [2]

每经AI快讯，9月12日，恒生指数上涨1.16%。南向资金今日净买入73.31亿港元。 （记者 陈鹏程） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 南向资金成交活跃个股榜单中，净买入个股共9只，金额最多的是阿里巴巴-W（9988.HK，收盘价： 151.1港元），净买入43.804亿港元；净卖出个股共4只，金额最多的是美团-W（3690.HK，收盘价： 96.55港元），净卖出16.820亿港元。 | 南向资金今日成交活跃个股榜单 | | --- | | 代码 | 简称 | 收盘价 | 涨跌幅 | 净买入金额 | | | --- | --- | --- | --- | --- | --- | | | | (港元) | (%) | (亿港元) | | | 9988.HK | 阿里巴巴-W | 151.1 | 5.44 | 43.80 | = | | 0700.HK | 腾讯控股 | 643.5 | 2.22 | 9.29 | . | | 9992.HK | 泡泡玛特 | 276.8 | 1.24 | 6.42 | = | | 1347.HK | 华虹半导体 | 50. ...

Core Insights - The article highlights a significant influx of capital into the Hong Kong innovative pharmaceutical sector, driven by southbound funds and ETF investments, indicating strong market confidence in Chinese innovative drug companies [4][12]. Fund Flows - On September 11, southbound funds purchased HKD 18.989 billion worth of Hong Kong stocks, with innovative pharmaceuticals accounting for six of the top ten active stocks, totaling a net buy of HKD 2.929 billion, which represents 36.07% of the top ten net buy scale [4][5]. - ETFs also saw substantial inflows, with a total net inflow of HKD 15.558 billion on the same day, where the pharmaceutical index captured eight spots in the top 30, with innovative pharmaceutical indices collectively attracting HKD 6.183 billion, making up 39.74% of the total inflow [6][8]. Performance Metrics - The Hong Kong innovative pharmaceutical index has shown a year-to-date increase of 107.29%, with a price-to-earnings (P/E) ratio at a historical high, indicating a strong performance but also raising caution regarding potential overvaluation [2][12]. - The article notes that since 2025, there have been 540 business development (BD) transactions globally in innovative drugs, with Chinese companies involved in 83 transactions, amounting to USD 84.531 billion, which is 51.73% of the global total [12]. Investor Sentiment - Global funds are increasingly allocating resources to Chinese assets, with a notable rise in hedge fund positions in China, reaching a two-year high, reflecting a positive outlook on the Chinese market [13][14]. - Both Goldman Sachs and Morgan Stanley emphasize that breakthroughs in technology and supportive policies in China are key factors attracting foreign investment [14].

Core Viewpoint - The pharmaceutical sector remains a key theme in bull markets, and investors should not overlook it despite recent fluctuations in stock performance [1]. Group 1: Market Performance - In August, technology stocks dominated the market, overshadowing other sectors, including pharmaceuticals, which had previously outperformed with over 40% gains [3][5]. - The innovative drug index has shown a lackluster performance recently, with only a 2.76% increase this month, significantly lagging behind other indices [3][5]. - Popular pharmaceutical stocks like Innovent Biologics and 3SBio have entered a phase of high-level consolidation, raising questions about the sustainability of the pharmaceutical sector's growth [5]. Group 2: Fund Performance - As of August 22, 97.3% of the 1,039 ETFs recorded positive returns, with an average return of 20.79% year-to-date [6]. - The pharmaceutical sector-related ETFs continue to lead in performance, with several Hong Kong innovative drug funds seeing returns exceeding 110% [7][11]. - A significant inflow of funds into Hong Kong innovative drug ETFs has been observed, with some funds increasing their share by over 150% since August 1 [13]. Group 3: Sector Analysis - The Hong Kong innovative drug sector remains strong, attracting continuous capital inflow, with a total scale of 178.7 billion [7]. - The medical device sector has emerged as a strong performer this month, with several ETFs seeing over 100% growth in fund shares [14][17]. - The medical device index has a historical valuation that suggests room for growth compared to previous bull markets [19]. Group 4: Investment Trends - Recent trends indicate a rotation in investment focus from innovative drugs to medical devices, as funds seek lower-priced opportunities within strong themes [20]. - The performance of traditional Chinese medicine and vaccine sectors has lagged, with funds showing less interest in these areas [21][26]. - The medical device sector's average gain of 41.8% this year indicates a broad-based rally, making related ETFs attractive for investors [30]. Group 5: Fund Manager Strategies - Fund managers are increasingly looking to realize profits from innovative drugs while reallocating to medical devices, reflecting a strategic shift in investment focus [37]. - The top-performing funds in the pharmaceutical sector have shown significant gains, but many are experiencing net redemptions as investors take profits [38][40]. - The performance of active pharmaceutical funds has improved, with many funds finally recovering from previous downturns [31][36].

格隆汇9月12日｜南下资金今日净买入港股73.31亿港元。其中： 净卖出美团-W 16.82亿、三生制药2.94亿、优必选2.28亿、哔哩哔哩-W 1.38亿。 净买入阿里巴巴-W 43.8亿、腾讯控股9.29亿、泡泡玛特6.42亿、华虹半导体4.01亿、康方生物2.25亿、 药捷安康-B 1.8亿； | | P TIE HOL | | | POLICALL | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | 深跌幅 | 净买入额(亿) | 成交额 | 名称 | 涨跌幅 | 净买入额(亿) | 成交额 | | 阿里巴巴-W | 5.4% | 20.76 | 87.74 L | 阿里巴-W | 5.4% | 23.04 | 63.89 L | | 美国-W | 0.0% | -16.35 | 50.99亿 | 腾讯控股 | 2.2% | 7.44 | 32.17 Z | | 中心同际 | -1.0% | -2.13 | 37.02 L | 小米集团-W | 0.9% | 1.94 | 23.17亿 | | 鹰讯控股 | 2.2% | ...

Core Insights - The Hong Kong stock market saw a net inflow of 73.31 billion HKD from northbound trading on September 12, with the Shanghai Stock Connect recording a net outflow of 14.87 billion HKD and the Shenzhen Stock Connect a net inflow of 88.18 billion HKD [1] Group 1: Stock Performance - Alibaba (09988) had a net inflow of 54.25 billion HKD, with total trading volume of 87.74 billion HKD, resulting in a net inflow of 20.76 billion HKD [2] - Tencent (00700) recorded a net inflow of 16.78 billion HKD, with a total trading volume of 31.72 billion HKD, leading to a net inflow of 1.85 billion HKD [2] - Pop Mart (09992) saw a net inflow of 8.70 billion HKD, with a total trading volume of 15.81 billion HKD, resulting in a net inflow of 1.60 billion HKD [2] Group 2: Notable Stocks - Alibaba (09988) received a net inflow of 43.8 billion HKD this week, totaling approximately 220 billion HKD in net inflows, driven by news of its internal chip development for AI models [4] - Tencent (00700) gained a net inflow of 9.29 billion HKD, with market analysts noting that its gaming and advertising businesses are entering a mature phase, making future growth challenging [5] - Pop Mart (09992) attracted a net inflow of 6.42 billion HKD, with positive outlooks from analysts regarding upcoming product launches and seasonal sales [5] Group 3: Other Stocks - Semiconductor stocks like Hua Hong Semiconductor (01347) and SMIC (00981) received net inflows of 4.01 billion HKD and 830.3 million HKD respectively, amid reports of domestic chip development [6] - Kangfang Biologics (09926) had a net inflow of 2.25 billion HKD, supported by positive clinical data announcements [7] - Yaojie Ankang-B (02617) saw a net inflow of 1.8 billion HKD after being added to the Hong Kong Stock Connect list [7]